Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Gossypol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.89 |
| ▸ | MCL1 | Q07820 | 12/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gossypol SCHEMBL26123198 | 1.00 | MCL1 (1.00) | MCL1KDM4EMEN1NPC1USP2 | |
| Gossypol SCHEMBL28196907 | 0.99 | MCL1 (0.97) | MCL1KDM4EMEN1NPC1USP2 | |
| Gossypol SCHEMBL28138847 | 0.99 | MCL1 (0.97) | MCL1KDM4EMEN1NPC1USP2 | |
| Gossypol SCHEMBL4447834 | 0.96 | MCL1 (0.92) | MCL1KDM4EMEN1NPC1USP2 | |
| Gossypol SCHEMBL29025502 | 0.95 | MCL1 (0.90) | MCL1KDM4EMEN1NPC1USP2 | |
| Gossypol SCHEMBL27946529 | 0.95 | MCL1 (0.90) | MCL1KDM4EMEN1NPC1USP2 | |
| Gossypol SCHEMBL29355719 | 0.94 | MCL1 (1.00) | MCL1KDM4EMEN1NPC1USP2 | |
| Gossypol SCHEMBL30260519 | 0.94 | MCL1 (1.00) | MCL1KDM4EMEN1NPC1USP2 | |
| Gossypol SCHEMBL29798874 | 0.94 | MCL1 (1.00) | MCL1KDM4EMEN1NPC1USP2 | |
| Gossypol SCHEMBL3939 | 0.94 | MCL1 (1.00) | MCL1KDM4EMEN1NPC1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 991 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122081099-A | Free gossypol degrading bacterium YJQ-1 and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122036558-A | Gossypol derivative, preparation method thereof and application thereof in preparation of coronavirus 3CL protease inhibitor | 陕西盘龙药业集团股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4739300-A1 | MODULATORS OF IRON METABOLISM FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| CN-122012510-A | Gossypol specific nucleic acid aptamer and preparation method and application thereof | 新疆大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260108534-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | JAZZ PHARMACEUTICALS THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4707810-A1 | USE OF GLUT1 AS A MARKER FOR HEMATOLOGIC DISORDERS | Metafora Biosystems (FR) | 2026-03-11 | — | — | EP | claimed |
| US-20260007728-A1 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2026-01-08 | — | — | US | claimed |
| EP-4554613-A2 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2025-05-21 | — | — | EP | claimed |
| CN-119899373-A | (-) -Gossypol derivative and preparation method thereof and antioxidant | 武汉轻工大学 | 2025-04-29 | — | — | CN | claimed |
| WO-2025080282-A1 | COMBINATION THERAPY WITH CLK/DYRK INHIBITORS AND BCL2 INHIBITORS TO TREAT LEUKEMIA | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-04-17 | — | — | WO | claimed |
| CN-1557295-A | Gynecopathy therapeutic drug | 陕西盘龙制药集团有限公司 | 2004-12-29 | — | — | CN | claimed |
| CN-1529590-A | Compositions and methods to treat neovascularization and disease associated with thereof | ά����ķ����˾ | 2004-09-15 | — | — | CN | claimed |
| EP-1343487-A2 | METHODS AND COMPOSITIONS TO TREAT CONDITIONS ASSOCIATED WITH NEOVASCULARIZATION | Wackvom Limited (VG) | 2003-09-17 | — | — | EP | claimed |
| US-6608107-B2 | Administering gossypol; kits to treat patients | WACKVOM LIMITED (VG) | 2003-08-19 | — | — | US | claimed |
| US-20020137801-A1 | METHODS AND COMPOSITIONS TO TREAT CONDITIONS ASSOCIATED WITH NEOVASCULARIZATION | WACKVOM LIMITED (VG) | 2002-09-26 | — | — | US | claimed |
| WO-2002047673-A2 | METHODS AND COMPOSITIONS TO TREAT CONDITIONS ASSOCIATED WITH NEOVASCULARIZATION | WACKVOM LIMITED (VG) | 2002-06-20 | — | — | WO | claimed |
| US-5385936-A | Of adrenal glands, ovarian, thyroid, testicular, pituatary, prostate orbreast; administering orally | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF THE HEALTH AND HUMAN SERVICES (US) | 1995-01-31 | — | — | US | claimed |
| CN-87104130-A | The method and the pharmaceutical formulation that kill mouse with gossypol and derivant thereof | — | 1988-12-28 | — | — | CN | claimed |
| CN-85108568-A | MAKING ACETIC ACID COTTON PHENOL BY ACETONE-WATER DILUTION TECHNOLOGY | — | 1987-05-06 | — | — | CN | claimed |
| US-4381298-A | Oral male contraceptive composition | COULSON PATRICIA B | 1983-04-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108534-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | BCL2, BCL3, BCL2L1 | ESR1 1138/4885MCL1 8/4885KDM4E 1134/4885 |
| US-20260007728-A1 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | BCL3, BCL9, BCL9L | ESR1 2638/4885MCL1 9/4885KDM4E 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.